Viewing StudyNCT00240565



Ignite Creation Date: 2024-05-05 @ 12:05 PM
Last Modification Date: 2024-10-26 @ 9:20 AM
Study NCT ID: NCT00240565
Status: COMPLETED
Last Update Posted: 2012-08-13
First Post: 2005-10-14

Brief Title: Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkins Lymphoma
Sponsor:
Organization: GlaxoSmithKline

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 93
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE2
Observational Models:
Time Perspective List:
Who Masked List: